The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 09, 2026

Filed:

Dec. 06, 2019
Applicant:

Georgia State University Research Foundation, Inc., Atlanta, GA (US);

Inventors:

Karuna Mittal, Atlanta, GA (US);

Padmashree Rida, Atlanta, GA (US);

Ritu Aneja, Atlanta, GA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
G01N 33/575 (2026.01); G01N 33/50 (2006.01); G01N 33/57515 (2026.01); G01N 33/68 (2006.01); G16H 30/40 (2018.01); G16H 50/30 (2018.01);
U.S. Cl.
CPC ...
G01N 33/57595 (2026.01); G01N 33/5026 (2013.01); G01N 33/5091 (2013.01); G01N 33/57515 (2026.01); G01N 33/6875 (2013.01); G16H 30/40 (2018.01); G16H 50/30 (2018.01);
Abstract

Embodiments may provide capability to predict the 10-year risk of local recurrence of ductal carcinoma in situ (DCIS) conditions or other non-invasive carcinomas in situ. Embodiments may evaluate the severity and frequency of numerical and structural CA present within DCIS, and may assign a quantitative centrosomal amplification score (CAS) to each sample. For example, a method of determining the risk profile of a carcinoma in situ in a patient may comprise determining severity and frequency of numerical and structural centrosome amplification present within a sample of a carcinoma in situ from the patient and determining at least one centrosome amplification score (CAS) value for the sample based on the determined severity and frequency of numerical and structural centrosome amplification in the sample, wherein the determined at least one CAS value provides a measure of a level of a 10-year risk of local recurrence associated with the carcinoma in situ.


Find Patent Forward Citations

Loading…